Home/Pipeline/CTLs Therapy

CTLs Therapy

Cancer

Pre-clinical/Early ClinicalActive

Key Facts

Indication

Cancer

Phase

Pre-clinical/Early Clinical

Status

Active

Company

Essen Biotech

About Essen Biotech

Essen Biotech is a private, clinical-stage biotech firm pioneering personalized cellular and gene therapies for oncology and genetic disorders. Leveraging a broad platform encompassing CAR-T, TILs, NK cells, CRISPR, and MSC therapies, the company aims to address unmet medical needs through cutting-edge research. While its website suggests a global patient-facing service model, the core appears to be therapeutic development, likely positioning it as a pre-revenue entity advancing programs through clinical trials. Key challenges include navigating complex clinical pathways, securing sustained funding, and differentiating in the competitive cell therapy landscape.

View full company profile

Therapeutic Areas

Oncology Genetic Diseases Regenerative Medicine

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active